Aardvark Therapeutics (AARD) Receivables (2025)

Aardvark Therapeutics (AARD) reported Receivables of $1.4 million for Q3 2025, little changed sequentially from $1.4 million in Q2 2025.

Aardvark Therapeutics (AARD) Receivables (2025) Analysis & Trends

Aardvark Therapeutics (AARD) has 1 years of Receivables data on file, last reported at $1.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Aardvark Therapeutics	139.40 Mn	19.44 Mn	-	-

Download Data